Nurix Therapeutics FY Conference Summary Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Event**: 44th Annual JPMorgan Healthcare Conference - **Date**: January 12, 2026 Key Industry Insights - **Emerging Class of Drugs**: Nurix is focused on establishing degrader-based mechanisms as a new class of therapeutics, which are expected to be as significant as antibodies and nucleic acid-based therapies [2][3] - **Targeted Protein Degraders**: These small molecule drugs can knock down protein levels effectively and are orally deliverable, offering a broader market opportunity compared to traditional therapies [3][4] Core Company Highlights - **2025 Achievements**: - Entered pivotal trials with Daybreak 201 study for CLL (Chronic Lymphocytic Leukemia) [4] - Reported an 83% objective overall response rate in heavily pre-treated patients [4][5] - Calculated a progression-free survival (PFS) of 22.1 months across all doses tested [5][16] - Secured a strong financial position with $250 million from a follow-on offering and approximately $650 million in cash and investments [6] Pipeline Developments - **Bexabrutadeg**: Lead BTK (Bruton’s Tyrosine Kinase) degrader, currently in pivotal studies with promising results [5][6] - **Partnerships**: Collaborations with Gilead for IRAK4 degrader and Sanofi for STAT6 degrader, both in various stages of clinical trials [6][29] - **Upcoming Trials**: - Phase 3 confirmatory study against Pirtobrutinib, a non-covalent inhibitor, to demonstrate the superiority of degraders [24][25] - Combination studies with Bexabrutadeg and other agents like Venetoclax and rituximab [26] Competitive Positioning - **Best-in-Class Potential**: Bexabrutadeg is positioned as a potential best-in-class agent due to its unique degradation mechanism, which is expected to outperform traditional inhibitors [35][42] - **Comparative Efficacy**: Bexabrutadeg shows a higher overall response rate (83%) compared to Pirtobrutinib (65%) and a longer median duration of response [20][21] Market Opportunities - **Large Patient Population**: Approximately 60,000 patients initiate treatment annually in the second and third lines, with current BTK inhibitor sales at $12.5 billion per year [27] - **Expansion into Autoimmune Diseases**: Plans to explore Bexabrutadeg in autoimmune indications, leveraging its safety profile and efficacy [28][45] Financial and Strategic Outlook - **Financial Health**: Strong balance sheet with significant cash reserves to support ongoing and future trials [6] - **Strategic Focus**: Aiming to establish a substantial IND portfolio covering multiple indications, with a focus on de-risking oncology products [32][33] Additional Insights - **Resistance to Current Therapies**: Bexabrutadeg is effective against all known resistance mutations associated with BTK inhibitors, providing a significant advantage in treatment [12][21] - **CNS Activity**: Notable efficacy in treating CNS involvement in CLL, opening avenues for non-malignant CNS diseases like multiple sclerosis [44] Conclusion Nurix Therapeutics is positioned at the forefront of a transformative approach in oncology and autoimmune disease treatment through its innovative degrader technology, with a robust pipeline and strategic partnerships that enhance its competitive edge in the market.

Nurix Therapeutics (NasdaqGM:NRIX) Conference Call Summary Company Overview - Nurix Therapeutics is focused on developing innovative therapies for patients with chronic lymphocytic leukemia (CLL) and other diseases, particularly through targeted protein degradation [1][2] Key Points on Bexabrutadeg (BexDeg) - **Product Definition**: Bexabrutadeg is a best-in-class BTK (Bruton’s tyrosine kinase) degrader, recognized for its unique pharmacology and potential to overcome resistance mutations associated with existing BTK inhibitors [2][4] - **Clinical Efficacy**: - Achieved an **83% overall response rate** in heavily pretreated CLL patients, with a **median progression-free survival (PFS)** of **22.1 months** [10][36] - Demonstrated efficacy against various resistance mutations, outperforming traditional BTK inhibitors [5][10] - Notably, **96% disease control rate** in a challenging patient population [32] - **Safety Profile**: - Treatment-related adverse events were reported in **75%** of patients, with a low incidence of severe events [25][26] - No grade 5 toxicities or dose-limiting toxicities (DLTs) were observed, indicating a favorable safety profile [25][50] - **Mechanism of Action**: - Bexabrutadeg can degrade up to **10,000 BTK proteins per hour**, showcasing its catalytic nature and differentiating it from traditional inhibitors [8] - It addresses both the kinase and scaffolding functions of BTK, providing a significant therapeutic advantage [6][7] Pipeline and Future Development - **Clinical Trials**: - Initiated the **Daybreak series of trials** aimed at accelerated approval, with plans for randomized confirmatory trials [11][12] - Future studies will explore combination therapies with other agents, including venetoclax [60][61] - **Regulatory Approvals**: - Bexabrutadeg has received approval from the FDA, EMA, and MHRA, marking a significant milestone for Nurix [52][53] - **Market Potential**: - The company anticipates a high economic value for Bexabrutadeg, given the significant patient populations in the U.S. and Canada that can benefit from this therapy [12] Waldenstrom's Macroglobulinemia Data - **Patient Population**: - The study included **31 patients** with Waldenstrom's, with a median age of **71** and a high prevalence of previous BTK inhibitor exposure [42][43] - **Efficacy Results**: - The objective response rate was **75%**, with a major response rate of **60%** [47][50] - Responses were observed even in patients with CNS involvement, indicating the drug's potential in difficult-to-treat populations [49] - **Safety Profile**: - Similar to CLL, most treatment-related adverse events were low-grade and manageable, with no new safety concerns identified [45][50] Competitive Landscape - **Comparison with Pirtobrutinib**: - Bexabrutadeg's objective response rates and durability of response are superior to those reported for Pirtobrutinib, highlighting its potential as a more effective treatment option [56][57] Conclusion - Nurix Therapeutics is positioned as a significant player in the oncology space with Bexabrutadeg, demonstrating promising clinical efficacy and safety in CLL and Waldenstrom's macroglobulinemia. The company is advancing its clinical programs and exploring combination therapies to enhance treatment outcomes for patients with hematologic malignancies [54][62]